T14928 |
Agerafenib hydrochloride
|
1227678-26-3
|
98%
|
|
Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM).
|
T10823 |
Trans-Pralsetinib
|
2097132-93-7
|
98%
|
|
trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET) extracted from patent US20170121312A1 (Compound Example 129).
|
T16995 |
TAS05567
|
1429038-15-2
|
98%
|
|
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
|
T35384 |
TPX-0046
|
2359650-19-2
|
98%
|
|
TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.
|
T8402 |
Regorafenib Hydrochloride
|
835621-07-3
|
98%
|
|
Regorafenib Hydrochloride is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor ac...
|
T7418 |
BBT594
|
882405-89-2
|
98%
|
|
BBT594(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.
|
T2032 |
WHI-P180
|
211555-08-7
|
98%
|
|
WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
|
TQ0277 |
Pralsetinib
|
2097132-94-8
|
98%
|
|
Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RE...
|
T2358 |
ENMD-2076
|
934353-76-1
|
98%
|
|
ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.
|
TQ0059 |
Ilorasertib
|
1227939-82-3
|
98%
|
|
Ilorasertib (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A/Aurora B/Aurora C (IC50s: 120 nM/7 nM/1 nM). It also suppress...
|
T22349 |
JNJ-38158471
|
951151-97-6
|
98%
|
|
CS-2660, a highly selective, orally available, well tolerated VEGFR2 inhibitor with IC50 of 40 nM, inhibits closely related tyrosine kinases such as Ret and Kit ...
|
T16923 |
SPP-86
|
1357349-91-7
|
98%
|
|
SPP-86 inhibits RET-induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling. SPP-86 also inhibits RET-induced estrogen receptorα phosphorylation i...
|
T6028 |
PF 477736
|
952021-60-2
|
98%
|
|
PF-477736 is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
|
T10624 |
BT-13
|
924537-98-4
|
98%
|
|
BT-13 is a selective agonist of glial cell line-derived neurotrophic factor (GDNF) receptor RET independently of GFLs. BT-13 promotes neurite growth from sensory...
|
T2094 |
Danusertib
|
827318-97-8
|
98%
|
|
Danusertib is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may ...
|
T9445 |
Vepafestinib
|
2129515-96-2
|
98%
|
|
Vepafestinib is a RET inhibitor with potential antineoplastic activity[1].
|
T20742 |
TG-89
|
936091-56-4
|
98%
|
|
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cer...
|
T2282 |
RPI-1
|
269730-03-2
|
98%
|
|
RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
|
T3065 |
TG101209
|
936091-14-4
|
98%
|
|
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
|
T2070 |
Agerafenib
|
1188910-76-0
|
98%
|
|
CEP-32496 is a highly potent inhibitor of BRAF.
|